Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary) ; Vincristine
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- 05 Mar 2018 Planned number of patients changed from 37 to 22.
- 05 Mar 2018 The primary endpoint has been changed from Progression-free survival (PFS) to Object response rate (ORR) at 12 weeks.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.